Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Gains from Investment Securities: 2013-2024

Historic Gains from Investment Securities for Neurogene (NGNE) over the last 12 years, with Dec 2024 value amounting to $60,000.

  • Neurogene's Gains from Investment Securities was N/A to $13,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $102,000, marking a year-over-year change of. This contributed to the annual value of $60,000 for FY2024, which is 30.43% up from last year.
  • Neurogene's Gains from Investment Securities amounted to $60,000 in FY2024, which was up 30.43% from $46,000 recorded in FY2023.
  • Over the past 5 years, Neurogene's Gains from Investment Securities peaked at $10.4 million during FY2020, and registered a low of $46,000 during FY2023.
  • Over the past 3 years, Neurogene's median Gains from Investment Securities value was $60,000 (recorded in 2024), while the average stood at $65,667.
  • In the last 5 years, Neurogene's Gains from Investment Securities spiked by 776.82% in 2020 and then plummeted by 94.26% in 2022.
  • Yearly analysis of 5 years shows Neurogene's Gains from Investment Securities stood at $10.4 million in 2020, then tumbled by 84.72% to $1.6 million in 2021, then tumbled by 94.26% to $91,000 in 2022, then slumped by 49.45% to $46,000 in 2023, then skyrocketed by 30.43% to $60,000 in 2024.